Skip to main content
Boris Sepesi, MD, Thoracic Surgery, Houston, TX, University of Texas M.D. Anderson Cancer Center

BorisSepesiMD

Thoracic Surgery Houston, TX

Cardiovascular Surgery

Assistant Professor UT MDACC

Dr. Sepesi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Sepesi's full profile

Already have an account?

Education & Training

  • University of Texas MD Anderson Cancer Center/University of Texas Medical School at Houston
    University of Texas MD Anderson Cancer Center/University of Texas Medical School at HoustonFellowship, Thoracic Surgery, 2011 - 2013
  • University of Rochester
    University of RochesterResidency, Surgery, 2005 - 2011
  • University of Colorado
    University of ColoradoResidency, Internal Medicine, 2004 - 2004
  • Jagiellonian University Medical College
    Jagiellonian University Medical CollegeClass of 2004

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • CO State Medical License
    CO State Medical License 2023 - 2025
  • TX State Medical License
    TX State Medical License 2013 - 2024
  • OK State Medical License
    OK State Medical License 2020 - 2021
  • NY State Medical License
    NY State Medical License 2008 - 2013
  • American Board of Surgery Surgery
  • American Board of Thoracic Surgery Thoracic and Cardiac Surgery

Awards, Honors, & Recognition

  • Fellow (FACS) American College of Surgeons

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • My Top 5 Most Practice-Changing Presentations at WCLCOctober 2018

Press Mentions

  • Foundation Medicine Partners with Lung Cancer Research Foundation and the Lung Cancer Mutation Consortium on Screening Trial to Enable Precision Therapy
    Foundation Medicine Partners with Lung Cancer Research Foundation and the Lung Cancer Mutation Consortium on Screening Trial to Enable Precision TherapyJune 3rd, 2022
  • Circulating Cellular Determinants to Predict Response to Anti-PD-1 Monotherapy in Patients with Malignant Pleural Mesothelioma
    Circulating Cellular Determinants to Predict Response to Anti-PD-1 Monotherapy in Patients with Malignant Pleural MesotheliomaMay 15th, 2022
  • Adding Atezolizumab to Neoadjuvant Cisplatin-Pemetrexed a Feasible Option in Malignant Pleural Mesothelioma
    Adding Atezolizumab to Neoadjuvant Cisplatin-Pemetrexed a Feasible Option in Malignant Pleural MesotheliomaOctober 15th, 2021
  • Join now to see all

Professional Memberships

Hospital Affiliations